Clinical Trial Update: A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update examining multiple drug combinations including BI 765063, Ezabenlimab, Cetuximab, and BI 836880 for head and neck squamous cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• BI 765063
• BI 836880
• Cetuximab (cetuximab)
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC) | Phase 1 | Status: ACTIVE_NOT_RECRUITING